GoAI
Get started
TELA Bio, Inc. logo

TELA Bio, Inc.

TELA

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$0.6463

+$0.007 · +1.09%

Aug 21, 4:00 PM ET

Pre-market

$0.67

+$0.0237 · +3.67%

Aug 24, 6:49 AM ET

TELA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

90

Deep Value

Momentum

28

Weakening

Sentiment

55

Mixed

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Heather Getz
Listed since
Nov 7, 2019
Employees
218

Market position

Day range

Current $0.6463

52-week range

Current $0.6463

Open
$0.6799
Previous close
$0.6393
Volume
59.8K
0.4× average
Average volume
148.95K
Average daily volume
Market cap
28.92M USD
Beta
1.36
Market reference 1
50-day average
$0.763
-15.29% below average
200-day average
$0.8862
-27.07% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
60.21M USD
P/E (TTM)
-0.84×
P/B (TTM)
-2.34×
P/S (TTM)
0.36×
EV / EBITDA
-1.86×
Earnings yield
-70.09%
Free cash flow yield
-51.75%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
67.81%
Operating margin
-42.56%
Net margin
-51.53%
Return on equity
-615.10%
Return on assets
-47.69%
Return on invested capital
-53.21%

Financial health

Debt / equity
-3.57×
Current ratio
4.2×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends87%14%-58%-131%Gross margin, FY2021: 63.85%Gross margin, FY2022: 65.30%Gross margin, FY2023: 68.62%Gross margin, FY2024: 67.08%Gross margin, FY2025: 67.69%Operating margin, FY2021: -99.96%Operating margin, FY2022: -94.18%Operating margin, FY2023: -75.40%Operating margin, FY2024: -49.23%Operating margin, FY2025: -42.05%Net margin, FY2021: -112.94%Net margin, FY2022: -106.95%Net margin, FY2023: -79.83%Net margin, FY2024: -54.60%Net margin, FY2025: -48.37%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 63.85%. Gross margin FY2022 65.30%. Gross margin FY2023 68.62%. Gross margin FY2024 67.08%. Gross margin FY2025 67.69%. Operating margin FY2021 -99.96%. Operating margin FY2022 -94.18%. Operating margin FY2023 -75.40%. Operating margin FY2024 -49.23%. Operating margin FY2025 -42.05%. Net margin FY2021 -112.94%. Net margin FY2022 -106.95%. Net margin FY2023 -79.83%. Net margin FY2024 -54.60%. Net margin FY2025 -48.37%.

Income trends

Revenue

80.28M USD+15.84%

Operating income

−33.76M USD+1.06%

Net income

−38.83M USD-2.62%
Income trends across reported periods92.97M USD42.19M USD−8.58M USD−59.36M USDRevenue, FY2021: 29.46M USDRevenue, FY2022: 41.42M USDRevenue, FY2023: 58.45M USDRevenue, FY2024: 69.3M USDRevenue, FY2025: 80.28M USDOperating income, FY2021: −29.45M USDOperating income, FY2022: −39.01M USDOperating income, FY2023: −44.08M USDOperating income, FY2024: −34.12M USDOperating income, FY2025: −33.76M USDNet income, FY2021: −33.28M USDNet income, FY2022: −44.3M USDNet income, FY2023: −46.66M USDNet income, FY2024: −37.84M USDNet income, FY2025: −38.83M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 29.46M USD. Revenue FY2022 41.42M USD. Revenue FY2023 58.45M USD. Revenue FY2024 69.3M USD. Revenue FY2025 80.28M USD. Operating income FY2021 −29.45M USD. Operating income FY2022 −39.01M USD. Operating income FY2023 −44.08M USD. Operating income FY2024 −34.12M USD. Operating income FY2025 −33.76M USD. Net income FY2021 −33.28M USD. Net income FY2022 −44.3M USD. Net income FY2023 −46.66M USD. Net income FY2024 −37.84M USD. Net income FY2025 −38.83M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue80.28M USD69.3M USD58.45M USD41.42M USD29.46M USD
Cost of goods sold25.93M USD22.81M USD18.34M USD14.37M USD10.65M USD
Gross profit54.34M USD46.49M USD40.11M USD27.04M USD18.81M USD
Research and development9.22M USD8.81M USD9.62M USD8.94M USD6.74M USD
Selling, general, and administrative78.88M USD79.37M USD74.57M USD57.11M USD41.52M USD
Operating expenses88.1M USD80.6M USD84.19M USD66.05M USD48.26M USD
Interest expense5.25M USD5.29M USD5.22M USD4.05M USD3.6M USD
Depreciation and amortization1.01M USD1.01M USD808K USD1.19M USD535K USD
Operating income−33.76M USD−34.12M USD−44.08M USD−39.01M USD−29.45M USD
Net income−38.83M USD−37.84M USD−46.66M USD−44.3M USD−33.28M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-8.92%
11 comparable reports
Latest EPS result
-0.2
Estimate -0.17 · Miss by 15.10%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.12-0.18-0.23-0.29Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -0.23, estimate -0.24, surprise +4.17%, Beat. Q2 2025, reported May 8, 2025: actual -0.25, estimate -0.21, surprise -19.05%, Miss. Q3 2025, reported Aug 11, 2025: actual -0.22, estimate -0.18, surprise -22.22%, Miss. Q4 2025, reported Nov 13, 2025: actual -0.19, estimate -0.17, surprise -11.76%, Miss. Q1 2026, reported Mar 25, 2026: actual -0.16, estimate -0.18, surprise +11.11%, Beat. Q2 2026, reported May 12, 2026: actual -0.21, estimate -0.14, surprise -50.00%, Miss. Q3 2026, reported Aug 10, 2026: actual -0.2, estimate -0.174, surprise -15.10%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.19, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates23.03M20.84M18.65M16.47MQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual 17.65M USD, estimate 21.05M USD, surprise -16.15%, Miss. Q2 2025, reported May 8, 2025: actual 18.52M USD, estimate 17.35M USD, surprise +6.73%, Beat. Q3 2025, reported Aug 11, 2025: actual 20.2M USD, estimate 22.14M USD, surprise -8.79%, Miss. Q4 2025, reported Nov 13, 2025: actual 20.69M USD, estimate 21.04M USD, surprise -1.67%, Miss. Q1 2026, reported Mar 25, 2026: actual 20.87M USD, estimate 21.03M USD, surprise -0.79%, Miss. Q2 2026, reported May 12, 2026: actual 19.06M USD, estimate 18.6M USD, surprise +2.49%, Beat. Q3 2026, reported Aug 10, 2026: actual 19.29M USD, estimate 20.01M USD, surprise -3.59%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 20.04M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.25

1176.50% upside
Past 12 months12-month forecast

Price history unavailable

High $20.00Average $8.25Low $1.25

TELA news

seekingalpha.com

TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript

TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript

Read source
zacks.com

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.22 per share a year ago.

Read source
globenewswire.com

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today…

Read source
globenewswire.com

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced…

Read source
globenewswire.com

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today…

Read source
globenewswire.com

TELA Bio to Announce Second Quarter 2026 Financial Results

MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today…

Read source

TELA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TELA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
839.15K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
284.27K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research TELA

research.disclaimer